EUVIMEDEUVIMED entdecken
CrossrefInfokarte

HLA-DR modulation and PD-1/PD-L2 checkpoint signaling identify a mechanistic potency axis for mesenchymal stromal cell immunosuppression

Mahin Nikougoftar Zarif, Katia Lefsihane, Neda Khanlarkhani, Lina Sorvik, Jan Fredrik Talts, Katarina Le Blanc, Nadir Kadri

Stem Cells Translational Medicine · 2026-10-16 · 15 (11)

DOI: 10.1093/stcltm/szag090 ↗
AbstractBibliografische Angaben

Abstract

Abstract Introduction Mesenchymal stromal cells exhibit potent immunomodulatory properties and are under active investigation for the treatment of immune-mediated disorders. However, their clinical translation is hindered by the lack of standardized potency assays. Methods Here, we established a reproducible mixed lymphocyte reaction platform by systematically optimizing peripheral blood mononuclear cell donor composition, culture conditions, and co-culture ratios to define a robust activation window. Using this optimized mixed lymphocyte reaction-based potency assay, we compared bone marrow and adipose-derived mesenchymal stromal cells across independent donor batches. Results Both sources of mesenchymal stromal cells effectively suppressed T-cell proliferation, with the adipose-derived source demonstrating greater inhibitory activity under the experimental conditions, while a conserved lower threshold of suppression was observed across both sources. Mesenchymal stromal cells reduced early (CD25+) and late (CD25+ HLA-DR+) T-cell activation, with downregulation of CD25 and HLA-DR emerging as sensitive correlates of functional potency. Notably, bone marrow-derived mesenchymal stromal cells exerted stronger suppression of late-stage HLA-DR+ activation and preferentially inhibited CD8+ T-cell expansion, demonstrating source-dependent immunomodulatory functions. Mechanistically, this suppression was associated with modulation of the PD-1 pathway, characterized by decreased soluble PD-1, increased soluble PD-L1, and induction of soluble PD-L2 by mesenchymal stromal cells. PD-L2 levels inversely correlated with T-cell proliferation in the mixed lymphocyte reaction, supporting a PD-1/PD-L2 regulatory axis linked to mesenchymal stromal cell potency. Conclusion These findings support a standardized and mechanistically informed mixed lymphocyte reaction-based potency assay framework integrating functional suppression, HLA-DR modulation, and PD-1/PD-L2 pathway signaling as complementary indicators of mesenchymal stromal cell activity.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →